180 CLINICAL CHARACTERISTICS, CLINICAL RESPONSE, AND CLINICAL REMISSION STATUS IN ADULTS TREATED WITH USTEKINUMAB IN THE PHASE 3 UNITI STUDIES AT WEEK 6 AND WEEK 44 BY AGE AT CROHN'S DISEASE ONSET